Our understanding of secondary metabolite production in bacteria has been shaped primarily by studies of attached varieties such as symbionts, pathogens, and soil bacteria. Here we show that a strain of the single-celled, planktonic marine cyanobacterium
Prochlorococcus
—which conducts a sizable fraction of photosynthesis in the oceans—produces many cyclic, lanthionine-containing peptides (lantipeptides). Remarkably, in
Prochlorococcus
MIT9313 a single promiscuous enzyme transforms up to 29 different linear ribosomally synthesized peptides into a library of polycyclic, conformationally constrained products with highly diverse ring topologies. Genes encoding this system are found in variable abundances across the oceans—with a hot spot in a Galapagos hypersaline lagoon—suggesting they play a habitat- and/or community-specific role. The extraordinarily efficient pathway for generating structural diversity enables these cyanobacteria to produce as many secondary metabolites as model antibiotic-producing bacteria, but with much smaller genomes.
Aided by genome-mining strategies, knowledge of the prevalence and diversity of ribosomally synthesized natural products (RNPs) is rapidly increasing. Among these are the lantipeptides, posttranslationally modified peptides containing characteristic thioether cross-links imperative for bioactivity and stability. Though this family was once thought to be a limited class of antimicrobial compounds produced by gram-positive bacteria, new insights have revealed a much larger diversity of activity, structure, biosynthetic machinery, and producing organisms than previously appreciated. Detailed investigation of the enzymes responsible for installing the posttranslational modifications has resulted in improved in vivo and in vitro engineering systems focusing on enhancement of the therapeutic potential of these compounds. Although dozens of new lantipeptides have been isolated in recent years, bioinformatic analyses indicate that many hundreds more await discovery owing to the widespread frequency of lantipeptide biosynthetic machinery in bacterial genomes.
Highlights d CNS-Gipr KO mice are protected from diet-induced obesity and glucose intolerance d Acyl-GIP increases cFOS neuronal activity in key hypothalamic feeding centers d Acyl-GIP effects on body weight and food intake are absent/ blunted in CNS-mGipr KO mice d GLP-1/GIP dual-agonism loses superior potency over GLP-1 in CNS-mGipr KO mice.
Ribosomally synthesized and post-translationally modified
peptides
are a rapidly expanding class of natural products. They are typically
biosynthesized by modification of a C-terminal segment of the precursor
peptide (the core peptide). The precursor peptide also contains an
N-terminal leader peptide that is required to guide the biosynthetic
enzymes. For bioengineering purposes, the leader peptide is beneficial
because it allows promiscuous activity of the biosynthetic enzymes
with respect to modification of the core peptide sequence. However,
the leader peptide also presents drawbacks as it needs to be present
on the core peptide and then removed in a later step. We show that
fusing the leader peptide for the lantibiotic lacticin 481 to its
biosynthetic enzyme LctM allows the protein to act on core peptides
without a leader peptide. We illustrate the use of this methodology
for preparation of improved lacticin 481 analogues containing non-proteinogenic
amino acids.
Lantibiotics are ribosomally synthesized and post-translationally modified peptide antibiotics containing the characteristic thioether cross-links lanthionine and methyllanthionine. To date, no analogues of lantibiotics that contain nonproteinogenic amino acids have been reported. In this study, in vitro-reconstituted lacticin 481 synthetase was used in conjunction with synthetic peptide substrates containing nonproteinogenic amino acids to generate 11 analogues of lacticin 481. These analogues contained sarcosine and aminocyclopropanoic acid in place of Gly5, d-valine at position 6, 4-cyanoaminobutyric acid in place of Glu13, β3-homoarginine at the position of Asn15, N-butylglycine and β-Ala at Met16, naphthylalanine (Nal) at Trp19, 4-pyridynylalanine (Pal) at Phe21, and homophenylalanine (hPhe) at Phe23. Of these analogues, the Trp19Nal and Phe23hPhe mutants provided zones of inhibition larger than the parent compound in agar diffusion assays against the indicator strains Lactococcus lactis HP and Bacillus subtilis 6633. These two compounds also demonstrated improved MIC values against liquid cultures of L. lactis HP.
Zinc‐chronized gelling: Selective zinc‐triggered hydrogel formation is realized by the self‐assembly of a de novo designed peptide (see picture). A non‐natural, zinc‐binding aminocarboxylate residue is incorporated into the peptide and is used to trigger folding, assembly, and subsequent gelation.
Disulfide bonds are essential for the structural stability and biological activity of many bioactive peptides. However, these bonds are labile to reducing agents, which can limit the therapeutic utility of such peptides. Substitution of a disulfide bond with a reduction-resistant cystathionine bridge is an attractive means of improving stability while imposing minimal structural perturbation to the peptide. We have applied this approach to the therapeutic complement inhibitor compstatin, a disulfide-containing peptide currently in clinical trials for age-related macular degeneration, in an effort to maintain its potent activity while improving its biological stability. Thioether-containing compstatin analogues were produced via solid-phase peptide synthesis utilizing orthogonally-protected cystathionine amino acid building blocks and solid-supported peptide cyclization. Overall, the affinity of these analogues for their biological target and potent inhibition of complement activation were largely maintained when compared to those of the parent disulfide-containing peptides. Thus, the improved stability to reduction conferred by the thioether bond makes this new class of compstatin peptides a promising alternative for therapeutic applications. Additionally, the versatility of this synthesis allows for exploration of this disulfide-to-thioether substitution in a variety of other therapeutic peptides.
Lantibiotics are a large family of antibacterial peptide
natural
products containing multiple post-translational modifications, including
the thioether structures lanthionine and methyllanthionine. Efforts
to probe structure–activity relationships and engineer improved
pharmacological properties have driven the development of new methods
to produce non-natural analogues of these compounds. In this study,
solid-supported chemical synthesis was used to produce analogues of
the potent lantibiotic epilancin 15X, in order to assess the importance
of several N-terminal post-translational modifications for biological
activity. Surprisingly, substitution of these moieties, including
the unusual N-terminal d-lactyl moiety, resulted in relatively
small changes in the antimicrobial activity and pore-forming ability
of the peptides.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.